HeartBeam's study shows its credit card-sized ECG device combined with a risk algorithm accurately identifies heart attack risk, with AUC up to 92.9%. The postHeartBeam's study shows its credit card-sized ECG device combined with a risk algorithm accurately identifies heart attack risk, with AUC up to 92.9%. The post

HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

2026/06/03 23:04
Okuma süresi: 3 dk
Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen crypto.news@mexc.com üzerinden bizimle iletişime geçin.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating its credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain.

The proof-of-concept study, which evaluated 184 patients, found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. The AUC rose to 92.9% when a personal, symptom-free baseline ECG was available for comparison. AUC is a measure of a test’s ability to distinguish between those with and without a condition, with 100% being perfect.

The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The HeartBeam System is a cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence.

HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025, as noted on the company’s cleared indications for use page. The company holds over 20 issued patents related to technology enablement.

The study’s implications are significant for emergency medicine, where rapid and accurate identification of heart attacks is critical. Currently, standard ECG machines are often bulky and limited to clinical settings. A portable device that can provide accurate risk assessment could enable earlier detection and treatment, potentially improving outcomes for patients with chest pain.

Physicians using the HeartBeam technology will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management.

The full press release is available at https://ibn.fm/ainxV. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s SEC filings, and undue reliance should not be placed on them.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk.

The post HeartBeam Study Shows Portable ECG Device Can Help Identify Heart Attack Risk appeared first on citybuzz.

Piyasa Fırsatı
Humans.ai Logosu
Humans.ai Fiyatı(HEART)
$0.0005053
$0.0005053$0.0005053
-21.87%
USD
Humans.ai (HEART) Canlı Fiyat Grafiği

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen crypto.news@mexc.com ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage